ERBB2 and cervical cancer: Vedicilimumab has promising efficacy in Her2-positive gynecological tumors, has been approved for marketing in gastric cancer and uroepithelial cancer indications in China, has a price advantage, and can be applied individually with super-indications in HER-2-positive cervical cancer patients.